Both inner and outer discs swing away from the unit for cleaning of a pharmaceutical-grade pin mill from Munson Machinery.
A new pharmaceutical-grade pin mill (i.e., centrifugal impact mill), model CIM-18-S316 from Munson Machinery, grinds friable powders, flakes, and granules into controlled particle sizes ranging from coarse to fine. Unlike conventional pin mills in which the static outer disc is removable but the inner rotating disc is not, the outer and inner discs can swing away from the unit on cantilevered arms, providing full access to both sides of both discs and the mill housing for rapid cleaning and sanitizing.
High-speed rotation of the inner disc creates centrifugal force that accelerates bulk material entering the central inlet of the opposing stationary disc. As material travels from the center to the periphery of the discs at high speed, it passes through a path of five intermeshing rows of precision-machined, rotating and stationary impactor pins, with the desired tight particle size distribution obtained by controlling the rotor speed. Setting the infinitely variable rotor speed between several hundred rpm and 5400 rpm provides the flexibility to use the machine for coarse grinding and de-agglomerating as well as for fine grinding down to 400 mesh.
Constructed of stainless steel, the unit features a sanitary butterfly valve on the air intake, sanitary fittings at the material intake and discharge, and a wash-down-duty motor. Vertical orientation of the mill housing on tubular stainless steel legs results in a smaller footprint than horizontally-oriented units.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.